ES2581488T3 - Nuevos métodos para el tratamiento de enfermedades inflamatorias - Google Patents

Nuevos métodos para el tratamiento de enfermedades inflamatorias Download PDF

Info

Publication number
ES2581488T3
ES2581488T3 ES10761935.5T ES10761935T ES2581488T3 ES 2581488 T3 ES2581488 T3 ES 2581488T3 ES 10761935 T ES10761935 T ES 10761935T ES 2581488 T3 ES2581488 T3 ES 2581488T3
Authority
ES
Spain
Prior art keywords
treatment
bssl
inflammatory diseases
new methods
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10761935.5T
Other languages
English (en)
Inventor
Olle Hernell
Susanne Lindquist
Lennart Gustav Lundberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipum AB
Original Assignee
Lipum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipum AB filed Critical Lipum AB
Application granted granted Critical
Publication of ES2581488T3 publication Critical patent/ES2581488T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)

Abstract

Composición farmacéutica que comprende un antagonista de BSSL y un portador o excipiente farmacéuticamente aceptable para su uso en la prevención, la profilaxis y/o el tratamiento de artritis reumatoide, en la que el antagonista de BSSL es (i) un anticuerpo o un fragmento de anticuerpo que se une específicamente a BSSL humana, o (ii) una molécula de iARN o un polinucleótido antisentido que comprende una secuencia complementaria a una parte de una secuencia de polinucleótido que codifica para BSSL humana o una secuencia complementaria a la misma.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20

Claims (1)

  1. imagen1
ES10761935.5T 2009-04-08 2010-04-06 Nuevos métodos para el tratamiento de enfermedades inflamatorias Active ES2581488T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0950228 2009-04-08
SE0950228 2009-04-08
US25422109P 2009-10-23 2009-10-23
US254221P 2009-10-23
PCT/SE2010/050377 WO2010117325A1 (en) 2009-04-08 2010-04-06 New methods for treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
ES2581488T3 true ES2581488T3 (es) 2016-09-06

Family

ID=42936433

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10761935.5T Active ES2581488T3 (es) 2009-04-08 2010-04-06 Nuevos métodos para el tratamiento de enfermedades inflamatorias

Country Status (8)

Country Link
US (4) US8597650B2 (es)
EP (3) EP3061463A1 (es)
CN (1) CN102458464B (es)
AU (1) AU2010235238B2 (es)
CA (1) CA2762187C (es)
ES (1) ES2581488T3 (es)
NZ (1) NZ596218A (es)
WO (1) WO2010117325A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2581488T3 (es) * 2009-04-08 2016-09-06 Lipum Ab Nuevos métodos para el tratamiento de enfermedades inflamatorias
US8867800B2 (en) 2009-05-27 2014-10-21 James R. Glidewell Dental Ceramics, Inc. Method of designing and fabricating patient-specific restorations from intra-oral scanning of a digital impression
EP3288961B8 (en) * 2015-04-27 2022-04-27 MacKay Memorial Hospital Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
AU2016261279B2 (en) 2015-05-10 2020-12-10 Ventana Medical Systems, Inc. Compositions and methods for simultaneous inactivation of alkaline phosphatase and peroxidase enzymes during automated multiplex tissue staining assays
EP3999115A4 (en) * 2019-07-12 2023-11-22 LipUm AB NEW BSSL ANTIBODIES

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
DK1730270T3 (en) 2004-03-31 2016-06-06 Université D'aix-Marseille Glycopeptides DERIVED FROM pancreatic STRUCTURES, ANTIBODIES AND APPLICATIONS THEREOF IN DIAGNOSIS AND therapeutics
ATE447714T1 (de) 2004-04-02 2009-11-15 Gunnar Bjursell Screeningverfahren für modulatoren der atherogenen lipoproteinen retention
US20090226904A1 (en) 2005-12-01 2009-09-10 University Of Bergen Diagnosis and treatment of exocrine pancreatic dysfunction and diabetes
EP1840573A1 (en) 2006-03-27 2007-10-03 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
WO2008148884A1 (en) * 2007-06-08 2008-12-11 Universite De La Mediterranee Compositions and methods for treating pancreatic tumors
US20100324075A1 (en) 2007-12-21 2010-12-23 University Of Cincinnati Therapeutic use of carboxyl ester lipase inhibitors
ES2581488T3 (es) * 2009-04-08 2016-09-06 Lipum Ab Nuevos métodos para el tratamiento de enfermedades inflamatorias

Also Published As

Publication number Publication date
US20120093829A1 (en) 2012-04-19
EP3061463A1 (en) 2016-08-31
CN102458464A (zh) 2012-05-16
EP2416803A4 (en) 2012-12-26
US20140099323A1 (en) 2014-04-10
EP2416803A1 (en) 2012-02-15
AU2010235238A1 (en) 2011-11-24
US8597650B2 (en) 2013-12-03
EP3831407A1 (en) 2021-06-09
CA2762187A1 (en) 2010-10-14
CA2762187C (en) 2017-08-01
US20160096899A1 (en) 2016-04-07
US9168299B2 (en) 2015-10-27
NZ596218A (en) 2013-07-26
US20200291136A1 (en) 2020-09-17
EP2416803B1 (en) 2016-04-06
WO2010117325A1 (en) 2010-10-14
AU2010235238B2 (en) 2015-01-29
CN102458464B (zh) 2016-08-03

Similar Documents

Publication Publication Date Title
ES2657226T3 (es) Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
AR126555A2 (es) Anticuerpos de oncostatina m humana y métodos de uso
UY34103A (es) Mezclas para la reduccion de la fisuracion por contraccion de morteros basados en cemento portland y hormigones
MX362591B (es) Uso de antagonistas de il-17.
CR10298A (es) Metodos y composiciones para antagonismo de rage
CL2008003061A1 (es) Compuestos tienopirimidina y pirazolopirimidina, inhibidores de quinasa mtor y quinasa pi3; composicion farmaceutica que comprende a dichos compuesto; y su uso para tratar aterosclerosis, artritis, cancer, entre otras enfermedades.
CL2015000094A1 (es) Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
EA201290254A1 (ru) Антагонисты il-17a
CL2013000100A1 (es) Composicion que comprende un agente de contraste para rayos x yodado y un portador o excipiente farmaceuticamente aceptable, donde la concentracion de yodo es de 10-170 mgl/ml; un metodo de examen con rayos x que comprende el uso de la composicion.
CL2012001627A1 (es) Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer.
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
CL2011002831A1 (es) Anticuerpo humanizado especifico de la forma protofibrilar del peptido a-beta; uso de dicho anticuerpo para tratar transtornos neurodegenerativos; composicion farmaceutica; celula que produce dichos anticuerpos; y procedimientos de preparacion de dicho anticuerpo.
EA201071291A2 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
CL2013003688A1 (es) Peptido coagonista del receptor de glucagon/glp-1; conjugado de dicho peptido; composicion farmacéutica; uso del peptido para tratar una enfermedad seleccionada del grupo de síndrome metabólico, diabetes, obesidad, esteatosis hepática y una enfermedad neurodegenerativa.
CL2007003191A1 (es) Compuestos derivados de pirimido-piridona, inhibidores de las proteina quinasas; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como artritis, sindrome de colon irritable, sindrome disneico agudo del adulto, epoc y para el
AR081750A1 (es) Anticuerpos anti-cd40
CL2008003197A1 (es) Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer.
AR088289A1 (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su utilizacion
EA201491356A1 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
CL2014000114A1 (es) Anticuerpo que se une a r-espondina 1 humana (rspo1); polipéptido que comprende un anticuerpo; composición farmacéutica que comprende el anticuerpo; uso para inhibor el crecimiento de un tumor.
NZ598127A (en) Cancer metastasis inhibitor
EA201390672A1 (ru) Схема приема cns 7056 (ремимазолама) для индуцирования седации
CL2011002416A1 (es) Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit.
EA201390803A1 (ru) Ингибиторы бромодомена и их применение